The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Tumor angiogenesis: therapeutic implications

Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187

Integrins: Versatility, modulation, and signaling in cell adhesion

Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,857

Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target

Fröhlich, E. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0469-5 · Cited by 29

Ursolic and oleanolic acids in combination therapy inhibit migration of colon cancer cells through down-regulation of the uPA/uPAR-dependent MMPs pathway

Pięt, M., & Paduch, R. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110202 · Cited by 28

Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells

Atmaca, H., & Uzunoğlu, S. (2014) · European Cytokine Network · doi:10.1684/ecn.2014.0347 · Cited by 28

The female breast and diabetes

Gouveri, E., Παπάνας, Ν., & Maltezos, E. S. (2011) · The Breast · doi:10.1016/j.breast.2011.02.019 · Cited by 28

Biaryls

Yet, L. (2018) · Wiley eBooks · doi:10.1002/9781118686263.ch4 · Cited by 28

Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor‐β‐mediated growth inhibition

Cohen-Solal, K., Merrigan, K. T., Chan, J. L. ‐., Goydos, J. S., Chen, W., Foran, D. J., Liu, F., Lasfar, A., & Reiß, M. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00858.x · Cited by 27

Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen–urokinase plasminogen activator receptor system–regulated secretion during breast cancer progression

Csiszar, A., Kutay, B., Wirth, S., Schmidt, U. G., Macho‐Maschler, S., Schreiber, M., Alacakaptan, M., Vogel, G. F., Aumayr, K., Huber, L. A., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0433-7 · Cited by 27

Secondary metabolites, antioxidant and anti-proteinase activities of methanolic extracts from cones of hop (Humulus lupulus L.) cultivars

Maliar, T., Nemeček, P., Ürgeová, E., Maliarová, M., Nesvadba, V., Krofta, K., Vulganová, K., Krošlák, E., & Kraic, J. (2016) · Chemical Papers · doi:10.1007/s11696-016-0034-2 · Cited by 27

Application of Molecular Modeling to Urokinase Inhibitors Development

Sulimov, V. B., Katkova, E. V., Oferkin, I. V., Sulimov, A. V., Romanov, A. N., Roschin, A. I., Beloglazova, I. B., Plekhanova, O. S., Va, T., & Sadovnichy, V. A. (2014) · BioMed Research International · doi:10.1155/2014/625176 · Cited by 26

PAI-1 4G/5G Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-Analysis

Wang, S., Cao, Q., Wang, X., Li, B., Tang, M., Yuan, W., Fang, J., Qian, J., Qin, C., & Zhang, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056797 · Cited by 26

Natural and Engineered Plasmin Inhibitors: Applications and Design Strategies

Swedberg, J. E., & Harris, J. M. (2012) · ChemBioChem · doi:10.1002/cbic.201100673 · Cited by 26

Inhibitory Effects of Butein on Cancer Metastasis and Bioenergetic Modulation

Liu, S., Chen, C., Chung, C., Wang, P., Wu, N., Cheng, J., Lai, Y., Sun, H., Peng, C.-Y., Tang, C., et al. (2014) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf502370c · Cited by 25

Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis

Kovacheva, M., Zepp, M., Berger, S. M., & Berger, M. R. (2014) · Oncotarget · doi:10.18632/oncotarget.2132 · Cited by 25

Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells

Cai, S., Zhang, P., Dong, S., Li, L., Cai, J., & Xu, M. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487348 · Cited by 25

Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma

Waldron, N. N., Oh, S., & Vallera, D. A. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.002 · Cited by 25

circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma

Xu, L., Wang, P., Li, L., Li, L., Huang, Y., Zhang, Y., Zheng, X., Yi, P., Zhang, M., & Xu, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01882-z · Cited by 24

Functional Genomic Analysis of the Impact of Camelina (Camelina sativa) Meal on Atlantic Salmon (Salmo salar) Distal Intestine Gene Expression and Physiology

Brown, T. D., Hori, T. S. F., Xue, X., Ye, C. L., Anderson, D. M., & Rise, M. L. (2016) · Marine Biotechnology · doi:10.1007/s10126-016-9704-x · Cited by 24

SP-8356, a (1S)-(–)-verbenone derivative, exerts in vitro and in vivo anti-breast cancer effects by inhibiting NF-κB signaling

Mander, S., Kim, D. H., Nguyen, H. T., Yong, H. J., Pahk, K., Kim, E.-Y., Lee, K., Seong, J. Y., Kim, W.-K., & Hwang, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-41224-y · Cited by 24

Is There a Genetic Predisposition to Postoperative Adhesion Development?

Thakur, M., Rambhatla, A., Qadri, F., Chatzicharalampous, C., Awonuga, M., Saed, G. M., Diamond, M. P., & Awonuga, A. O. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00356-7 · Cited by 24

Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study

Farag, P. S., AboulMagd, A. M., Hemdan, M. M., & Hassaballah, A. I. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106231 · Cited by 23

Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions

Bae, S. Y., Park, H. J., Hong, J., Lee, H., & Lee, S. K. (2016) · Scientific Reports · doi:10.1038/srep32258 · Cited by 23

6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease

Buckley, B. J., Majed, H., Aboelela, A., Minaei, E., Jiang, L., Fildes, K. J., Cheung, C., Johnson, D. C., Bachovchin, D. A., Cook, G. M., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126753 · Cited by 22

Down-Regulation of MiR-181c-5p Promotes Epithelial-to-Mesenchymal Transition in Laryngeal Squamous Cell Carcinoma via Targeting SERPINE1

Li, X., Wu, P., Tang, Y., Fan, Y., Liu, Y., Fang, X., Wang, W., & Zhao, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.544476 · Cited by 23

Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1

Kryza, T., Khan, T., Lovell, S., Harrington, B. S., Yin, J. X. M., Porazinski, S. R., Pajic, M., Koistinen, H. K., Rantala, J., Dreyer, T. F., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00783-w · Cited by 22

Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding

Dupont, D. M., Madsen, J. B., Hartmann, R. K., Tavitian, B., Ducongè, F., Kjems, J., & Andreasen, P. A. (2010) · RNA · doi:10.1261/rna.2338210 · Cited by 22

Emerging molecular markers for the prognosis of differentiated thyroid cancer patients

Baldini, E., Sorrenti, S., Tuccilli, C., Prinzi, N., Coccaro, C., Catania, A., Filippini, A., Bononi, M., Antoni, E. D., D’Armiento, M., et al. (2014) · International Journal of Surgery · doi:10.1016/j.ijsu.2014.05.054 · Cited by 21

Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours

Santos, A. A. F., Lopes, C. C. C., Marques, R. M., Amorim, I., Ribeiro, J., Frias, C., Vicente, C. M. F. D. B., Gärtner, F., & de Matos, A. (2010) · The Veterinary Journal · doi:10.1016/j.tvjl.2010.05.023 · Cited by 21

Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs

Ryu, J., Yoon, N. A., Lee, Y. K., Jeong, J. Y., Kang, S., Seong, H., Choi, J., Park, N., Kim, N., Cho, W. J., et al. (2014) · Molecules and Cells · doi:10.14348/molcells.2015.2259 · Cited by 21

Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?

van Dam, P. A., Coelho, A., & Rolfo, C. D. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.06.002 · Cited by 20

The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP

Zuppone, S., Assalini, C., Minici, C., Bertagnoli, S., Branduardi, P., Degano, M., Fabbrini, M. S., Montorsi, F., Salonia, A., & Vago, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59313-8 · Cited by 20

Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors

Buckley, B. J., Kumar, A. A., Aboelela, A., Bujaroski, R. S., Li, X., Majed, H., Fliegel, L., Ranson, M., & Kelso, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062999 · Cited by 20

Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling

Popa, N. L., Wergedal, J. E., Lau, K. ‐. W., Mohan, S., & Rundle, C. H. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0475-4 · Cited by 20

Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera

Provenzano, A. E., Posteri, R., Giansanti, F., Angelucci, F., Flavell, S. U., Flavell, D. J., Fabbrini, M. S., Porro, D., Ippoliti, R., Ceriotti, A., et al. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0589-1 · Cited by 20

uPAR, beyond regulating physiological functions, has orchestrated roles in cancer (Review)

Wang, L., Lin, X., & Sun, P. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5441 · Cited by 19

Knock‐down of plasminogen‐activator inhibitor‐1 enhances expression of E‐cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells

Lupu‐Meiri, M., Geras‐Raaka, E., Lupu, R., Shapira, H., Sandbank, J., Segal, L., Gershengorn, M. C., & Oron, Y. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24068 · Cited by 19

Urokinase Plasminogen Activator and Its Inhibitor Type‐1 as Prognostic Factors in Differentiated Thyroid Carcinoma Patients

Herceg, G. H., Herceg, D., Kralik, M., Kulić, A., Bence-Žigman, Z., Tomić-Brzac, H., Bračić, I., Kusačić-Kuna, S., & Prgomet, D. (2013) · Otolaryngology · doi:10.1177/0194599813496374 · Cited by 19

Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA)

Muthusamy, V., Messagie, J., Joossens, J., Lambeir, A., Haemers, A., der Veken, P. V., & Augustyns, K. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.040 · Cited by 18

Non-Canonical Smads Phosphorylation Induced by the Glutamate Release Inhibitor, Riluzole, through GSK3 Activation in Melanoma

Abushahba, W., Olabisi, O. O., Jeong, B., Boregowda, R. K., Wen, Y., Liu, F., Goydos, J. S., Lasfar, A., & Cohen-Solal, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047312 · Cited by 18

Targeting Tumor Cell Invasion and Dissemination In Vivo by an Aptamer That Inhibits Urokinase-type Plasminogen Activator through a Novel Multifunctional Mechanism

Bøtkjær, K. A., Deryugina, E. I., Dupont, D. M., Gårdsvoll, H., Bekes, E. M., Thuesen, C. K., Chen, Z., Ploug, M., Quigley, J. P., & Andreasen, P. A. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0349 · Cited by 18

Urokinase plasminogen activator, uPAR, MMP-2, and MMP-9 in the C6-glioblastoma rat model.

Schuler, P. J., Bendszus, M., Kühnel, S., Wagner, S., Hoffmann, T. K., Goldbrunner, R., & Vince, G. H. (2012) · PubMed · Cited by 18

Role of Plasminogen Activator Inhibitor-1 in Urokinase's Paradoxical In Vivo Tumor Suppressing or Promoting Effects

Jing, Y., Kovács, K., Kurisetty, V., Jiang, Z., Tsinoremas, N. F., & Merchan, J. R. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0145 · Cited by 18

Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice

Chen, D., & Williams, M. Y. B. J. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000219 · Cited by 18

Plectin as a prognostic marker in non-metastatic oral squamous cell carcinoma

Rikardsen, O., Magnussen, S. N., Svineng, G., Hadler‐Olsen, E., Uhlin‐Hansen, L., & Steigen, S. E. (2015) · BMC Oral Health · doi:10.1186/s12903-015-0084-9 · Cited by 17

Anticancer Role of PPAR γ Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes

Simpson‐Haidaris, P. J., Pollock, S. J., Ramon, S., Guo, N., Woeller, C. F., Feldon, S. E., & Phipps, R. P. (2010) · PPAR Research · doi:10.1155/2010/814609 · Cited by 18

HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis

Wu, S., Lin, C., Shih, H.-P., Ko, C., Lin, H.-Y., Lan, S.-W., Lin, H.-H., Tu, H.-F., Ho, C., Huang, H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0400-2 · Cited by 16

Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas

Ulisse, S., Baldini, E., Mottolese, M., Sentinelli, S., Gargiulo, P., Valentina, B., Sorrenti, S., Benedetto, A. D., Antoni, E. D., & D’Armiento, M. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-151 · Cited by 16

Mis-Trafficking of Endosomal Urokinase Proteins Triggers Drug-Induced Glioma Nonapoptotic Cell Death

Pasupuleti, N., Grodzki, A. C., & Gorin, F. A. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.096602 · Cited by 16

Emerging Lung Cancer Therapeutic Targets Based on the Pathogenesis of Bone Metastases

Oyewumi, M. O., Alazizi, A., Wehrung, D., Manochakian, R., & Safadi, F. F. (2014) · International Journal of Cell Biology · doi:10.1155/2014/236246 · Cited by 16

Efforts towards an On‐Target Version of the Groebke–Blackburn–Bienaymé (GBB) Reaction for Discovery of Druglike Urokinase (uPA) Inhibitors

Gladysz, R., Vrijdag, J. L., Rompaey, D. V., Lambeir, A., Augustyns, K., Winter, H. L. D., & der Veken, P. V. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201901917 · Cited by 16

CRITICAL REVIEW IN PHARMACEUTICAL SCIENCES

publisher, P. E. (2014) · ADVANCED SCIENCES INDEX · Cited by 16

HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor

Mekkawy, A. H., Morris, D. L., & Pourgholami, M. H. (2012) · Journal of Oncology · doi:10.1155/2012/950749 · Cited by 15

Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor

Harvey, T. J., Burdon, D., Steele, L. P., Ingram, N., Hall, G. D., Selby, P. J., Vile, R. G., Cooper, P. A., Shnyder, S. D., & Chester, J. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.45 · Cited by 15

Neoplastic progression of the human breast cancer cell line G3S1 is associated with elevation of cytoskeletal dynamics and upregulation of MT1-MMP

Brábek, J. (2010) · International Journal of Oncology · doi:10.3892/ijo_00000560 · Cited by 15

Urokinase Receptor Orchestrates the Plasminogen System in Airway Epithelial Cell Function

Stewart, C. E., & Sayers, I. (2013) · Lung · doi:10.1007/s00408-013-9450-z · Cited by 15

Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility

Oh, J., An, H. J., Kim, J. O., Jun, H. H., Kim, W. R., Kim, W. R., Oh, D., Kim, J. W., & Kim, J. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124334 · Cited by 15

Systematic evaluation of structure–property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride

Buckley, B. J., Aboelela, A., Majed, H., Bujaroski, R. S., White, K. L., Powell, A. K., Wang, W., Katneni, K., Saunders, J., Shackleford, D. M., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116116 · Cited by 15

Review of Cancer – Associated Fibroblasts and Therapies that Interfere with Their Activity

Takebe, N., Ivy, P. S., Timmer, W. C., Khan, N. I., Schulz, T., & Harris, P. J. (2013) · Tumor Microenvironment and Therapy · doi:10.2478/tumor-2013-0001 · Cited by 15

Effects of amiloride on physiological activity of stem cells of human lung cancer and possible mechanism

Zhang, H., Peng, C., Huang, H., Lai, Y., Hu, C., Li, F., & Wang, D. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.06.138 · Cited by 15

Virus-derived anti-inflammatory proteins: potential therapeutics for cancer

Zheng, D., Chen, H., Bartee, M. Y., Williams, J. M., Davids, J. A., Huang, E. H., Moreb, J. S., & Lucas, A. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.03.006 · Cited by 14

Genetic polymorphism of the plasminogen activator inhibitor‐1 is associated with an increased risk of endometrial cancer

Su, C., Yeh, K., Yeh, C., Wang, P.-H., Ho, E. S., Chou, M., Liu, K., Yang, S., & Yi, Y. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22035 · Cited by 14

In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines

Baldini, E., Presutti, D., Favoriti, P., Santini, S., Papoff, G., Tuccilli, C., Carletti, R., Gioia, C. R. T. D., Lori, E., Ferent, I. C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073724 · Cited by 14

Expression and anticancer activity analysis of recombinant human uPA1–43-melittin

Su, M., Chang, W., Cui, M., Yang, L., Wu, S., & Xu, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2750 · Cited by 14

The effects of MIBG on the invasive properties of HepG2 hepatocellular carcinoma cells

Yan, S., Guan, X.-Q., Liu, F.-Q., & Wang, Y. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1819 · Cited by 14

Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array

Völker, H., Weigel, M., Strehl, A., & Frey, L. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0737-5 · Cited by 14

Urokinase-Type Plasminogen Activator System in Norm and in Life-Threatening Processes (Review)

Kugaevskaya, E. V., Gureeva, T. A., Timoshenko, O. S., & Solovyeva, N. I. (2018) · General Reanimatology · doi:10.15360/1813-9779-2018-6-61-79 · Cited by 14

PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer

Wang, J., Peng, Y., Guo, H., & Li, C. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211037813 · Cited by 13

Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma?

Asanuma, K., Nakamura, T., Okamoto, T., Hagi, T., Kita, K., Nakamura, K., Matsuyama, Y., Yoshida, K., Asanuma, Y., & Sudo, A. (2022) · BMC Cancer · doi:10.1186/s12885-022-10106-4 · Cited by 13

A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study

Samulak, D., Malińska, A., Elzbieta, R., Ostalska‐Nowicka, D., Zabel, M., Dzięgiel, P., & Nowicki, M. O. (2012) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2012.03.031 · Cited by 13

Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts.

Chao, S.-C., Hu, D., Yang, P., Lin, C., & Yang, S. (2011) · PubMed Central · Cited by 13

The anti-metastatic efficacy of β-ionone and the possible mechanisms of action in human hepatocarcinoma SK-Hep-1 cells

Huang, C., Lyu, S.-C., Chen, J., & Hu, M. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511003473 · Cited by 13

Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue

Serpa, M. S., Mafra, R. P., Queiroz, S. I. M. L., da Silva, L. P., de Souza, L. B., & Pinto, L. P. (2018) · Brazilian Oral Research · doi:10.1590/1807-3107bor-2018.vol32.0093 · Cited by 13

Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis

Zengel, P., Ramp, D., Mack, B., Zahler, S., Berghaus, A., Muehlenweg, B., Gires, O., & Schmitz, S. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-92 · Cited by 13

Evaluation of Interactions between Urokinase Plasminogen and Inhibitors Using Molecular Dynamic Simulation and Free-Energy Calculation

Sa, R., Fang, L., Huang, M., Li, Q., Wei, Y., & Wu, K. (2014) · The Journal of Physical Chemistry A · doi:10.1021/jp5064319 · Cited by 12

Anticancer effects of methanol extract of Myrmecodia platytyrea Becc. leaves against human hepatocellular carcinoma cells via inhibition of ERK and STAT3 signaling pathways

Ju, A., Cho, Y.-C., Kim, B. R., Lee, S., Le, H. T. T., Vuong, H. L., & Cho, S. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4178 · Cited by 13

Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity

Salamouni, N. S. E., Buckley, B. J., Ranson, M., Kelso, M. J., & Yu, H. B. (2022) · Biophysical Reviews · doi:10.1007/s12551-021-00921-7 · Cited by 11

Advances in the understanding of the clinically relevant genetic pathways and molecular aspects of canine mammary tumours. Part 2: Invasion, angiogenesis, metastasis and therapy

Santos, A. A. F., & de Matos, A. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.03.029 · Cited by 11

Copenhagen Upar Prostate Cancer (CuPCa) Database: Protocol and Early Results

Lippert, S. K., Berg, K. D., Høyer‐Hansen, G., Lund, I. K., Iversen, P., Christensen, I. J., Brasso, K., & Røder, M. A. (2016) · Biomarkers in Medicine · doi:10.2217/bmm.15.114 · Cited by 11

Towards breast cancer targeting: Synthesis of tetrahydroindolocarbazoles, antibreast cancer evaluation, uPA inhibition, molecular genetic and molecular modelling studies

Ahmed, E. M., Sarhan, A. E., Elnaggar, D. H., Khattab, R. R., El-Naggar, M. H., El‐Messery, S. M., Hassan, G. S., Mounier, M. M., Mahmoud, K. M., Neama Ibrahim, A. L. I., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103332 · Cited by 11

Methylation-Driven Gene PLAU as a Potential Prognostic Marker for Differential Thyroid Carcinoma

Wu, M., Wei, B., Duan, S., Liu, M., Ouyang, D., Huang, P. F., & Chang, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.819484 · Cited by 11

ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer

Li, D., Hemati, H., Park, Y.-H., Taftaf, R., Zhang, Y., Liu, J., Cristofanilli, M., & Liu, X. (2023) · Cancers · doi:10.3390/cancers15102734 · Cited by 11

Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours

Anwar, S., Yanai, T., & Sakai, H. (2015) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2015.07.003 · Cited by 10

Plasminogen Activator System — Diagnostic, Prognostic and Therapeutic Implications in Breast Cancer

Leurer, C., & Rabbani, S. A. (2015) · InTech eBooks · doi:10.5772/59429 · Cited by 10

Urokinase Plasminogen Activator Receptor–PET with 68 Ga-NOTA-AE105

Skovgaard, D. C., Persson, M., & Kjær, A. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.02.003 · Cited by 10

SP-8356, a (1S)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF-κB and ERK Signaling

Kim, D. H., Yong, H. J., Mander, S., Nguyen, H. T., Nguyen, L. P., Park, H.-K., Cha, H. K., Kim, W.-K., & Hwang, J. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.200 · Cited by 10

Genetic and Epidemiological Similarities, and Differences Between Postoperative Intraperitoneal Adhesion Development and Other Benign Fibro-proliferative Disorders

Awonuga, A. O., Chatzicharalampous, C., Thakur, M., Rambhatla, A., Qadri, F., Awonuga, M., Saed, G. M., & Diamond, M. P. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00726-9 · Cited by 10

KCNF1 promotes lung cancer by modulating ITGB4 expression

Chen, C., Wu, P.-Y., Scoyk, M. M. V., Simko, S. A., Chou, C., & Winn, R. A. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00560-4 · Cited by 10

Multiscale Computational Modelling and Analysis of Cancer Invasion

Trucu, D., Domschke, P., Gerisch, A., & Chaplain, M. A. J. (2016) · Lecture notes in mathematics · doi:10.1007/978-3-319-42679-2_5 · Cited by 10

Application of nanotechnology to target and exploit tumour associated proteases

Cogo, F., Williams, R. D., Burden, R. E., & Scott, C. J. (2019) · Biochimie · doi:10.1016/j.biochi.2019.04.021 · Cited by 10

Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP): unravelling the tumor’s genetic landscape

Singh, H., Choudhary, H. B., Mandlik, D. S., Magre, M., Mohanto, S., Ahmed, M. G., Singh, B. K., Mishra, A. K., Kumar, A., Mishra, A., et al. (2024) · EXCLI journal · doi:10.17179/excli2024-7164 · Cited by 9

Diastereoselective synthesis and biological evaluation of new fluorine-containing α-aminophosphonates as anticancer agents and scaffold to human urokinase plasminogen activator inhibitors

Ciesielska, K., Wawrzyniak, D., Dutkiewicz, G., Kubicki, M., Jankowski, W., Hoffmann, M., Kamel, K., Rolle, K., & Pluskota‐Karwatka, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117116 · Cited by 9

Antimetastatic Properties of Tea Polyphenols

Bag, N., & Bag, A. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1638426 · Cited by 9

Inferred inactivation of the Cftr gene in the duodena of mice exposed to hexavalent chromium (Cr(VI)) in drinking water supports its tumor-suppressor status and implies its potential role in Cr(VI)-induced carcinogenesis of the small intestines

Mezencev, R., & Auerbach, S. S. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115773 · Cited by 10

Thromboembolism and bleeding in bladder cancer.

Fantony, J. J., & Inman, B. A. (2014) · PubMed · Cited by 9

A C to T polymorphism of urokinase plasminogen activator (P141L) is associated with Helicobacter pylori infection.

Goto, Y., Hagikura, S., Katsuda, N., & Hamajima, N. (2011) · PubMed · Cited by 8

Evaluation of the Therapeutic Effects of Harmine on Anaplastic Thyroid Cancer Cells

Baldini, E., Cardarelli, S., Campese, A. F., Lori, E., Fallahi, P., Virili, C., Forte, F., Pironi, D., Matteo, F. M. D., Palumbo, P., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021121 · Cited by 8

Effects of 5-h multimodal stress on the molecules and pathways involved in dendritic morphology and cognitive function

Xu, Y., Cheng, X., Cui, X., Wang, T., Liu, G., Yang, R., Wang, J., Bo, X., Wang, S., Zhou, W., et al. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.06.011 · Cited by 8

Ureteral Involvement and Diabetes Increase the Risk of Subsequent Bladder Recurrence after Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Hu, C., Tsai, Y.-C., Wang, S., Huang, C., Tai, H., Chen, C., Pu, Y., Lin, W., & Huang, K. (2015) · BioMed Research International · doi:10.1155/2015/527976 · Cited by 8

Tetrahydroindolocarbazoles (THICZs) as new class of urokinase (uPA) inhibitors: Synthesis, anticancer evaluation, DNA-damage determination, and molecular modelling study

El‐Sharief, M. A. M. S., El-Naggar, M. H., Ahmed, E. M., El‐Messery, S. M., Mahmoud, A. E. E.-D., Ali, M. M., Salem, L. M., Mahrous, K. F., & Sayed, M. T. E. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.06.033 · Cited by 8

Building a Molecular Trap for a Serine Protease from Aptamer and Peptide Modules

Dupont, D. M., Bjerregaard, N., Verpaalen, B., Andreasen, P. A., & Jensen, J. K. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00007 · Cited by 7

Microarray based analysis of gene regulation by mesenchymal stem cells in breast cancer

Zhang, M., Gao, C., Li, W. H., Yang, Y., Chang, L., Dong, J., Ren, Y. X., & Chen, D. D. (2017) · Oncology Letters · doi:10.3892/ol.2017.5776 · Cited by 7

The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies

Su, S.-C., Lin, C.-W., Yang, W.-E., Fan, W.-L., & Yang, S.-F. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1113260 · Cited by 145

Evolving role of uPA/uPAR system in human cancers

Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., & Sarkar, F. H. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.10.005 · Cited by 421

Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.

Choong, P., & Nadesapillai, A. P. W. (2003) · PubMed · doi:10.1097/01.blo.0000093845.72468.bd · Cited by 168

Urokinase Plasminogen Activator

Salajegheh, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-28140-7_57 · Cited by 3

The urokinase plasminogen activator system as a novel target for tumour therapy

Schmitt, M., Wilhelm, O. G., Reuning, U., Krüger, A., Harbeck, N., Lengyel, E. R., Graeff, H., Gänsbacher, B., Kessler, H., Bürgle, M., et al. (2000) · Fibrinolysis and Proteolysis · doi:10.1054/fipr.2000.0079 · Cited by 107